Case story

  • Germany

OECD NCP Germany - Transparency International Germany vs. Ratiopharm

Germany 2006

This case story originates from, a platform based on wiki style contributions from a virtual network or individuals, companies and organizations with relevant expertise. Though some of the information may be outdated or inaccurate due to the wiki-nature of the BASESwiki platform, they still present a valuable resource. ACCESS is reviewing and updating all BASESwiki case stories. 


Ratiopharm, a pharmaceuticals company and major producer of generic drugs, has allegedly engaged in unethical marketing practices, including bribing doctors and pharmacists in Belgium, Canada, Spain, Estonia and Germany.


In June 2006, the German NCP rejected the complaint citing the lack of transnational investment. Specifically, the NCP stated the complaint only dealt with alleged misbehaviour in Germany. In July 2006, Transparency International Germany resubmitted a revised and expanded complaint


OECD Watch case story page:


Contributor(s): This article was modified by Nicolaclayre (3), Kyle (2), and (1).